{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T07:18:20Z","timestamp":1788419900976,"version":"build-2803163510"},"reference-count":61,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,7]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>The term spondyloarthritis (SpA) encompasses a group of chronic inflammatory disorders of the joints, including ankylosing spondylitis, psoriatic arthritis, reactive arthritis, inflammatory bowel disease, juvenile SpA and undifferentiated SpA. These diseases can also present with uveitis, or intraocular inflammation, which can be controlled with biologics.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>Profound success has occurred with the tumor necrosis factor-\u03b1 inhibitors infliximab and adalimumab, moderate success with certolizumab pegol and golimumab and less encouraging results with etanercept. Promising results have also been demonstrated with interleukin-17 (IL-17) antagonists, such as secukinumab ixekizumab or combined IL-12 and 23 medications, such as ustekinumab.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>In cases of uveitis that require long-term control, biologics are an emerging and valuable class of medications for these patients, and may provide avenues to control both their underlying SpA and uveitis manifestations.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/bor.0000000000000619","type":"journal-article","created":{"date-parts":[[2019,5,17]],"date-time":"2019-05-17T23:03:43Z","timestamp":1558134223000},"page":"349-354","source":"Crossref","is-referenced-by-count":31,"title":["The use of biologics for uveitis associated with spondyloarthritis"],"prefix":"10.1097","volume":"31","author":[{"given":"Sruthi","family":"Arepalli","sequence":"first","affiliation":[{"name":"Casey Eye Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James T.","family":"Rosenbaum","sequence":"additional","affiliation":[{"name":"Casey Eye Institute"},{"name":"Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, Oregon, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230829","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1080\/09273948.2016.1234625","article-title":"Biologic therapy for HLA-B27-associated ocular disorders","volume":"25","author":"Gueudry","year":"2017","journal-title":"Ocul Immunol Inflamm"},{"key":"R2-20230829","doi-asserted-by":"crossref","first-page":"17","DOI":"10.7812\/TPP\/17-041","article-title":"Management of uveitis in spondyloarthropathy: current trends","volume":"22","author":"Gupta","year":"2018","journal-title":"Perm J"},{"key":"R3-20230829","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.semarthrit.2007.10.007","article-title":"Insights into the pathology and treatment of spondyloarthritis: from the bench to the clinic","volume":"38","author":"Davis","year":"2008","journal-title":"Semin Arthritis Rheum"},{"key":"R4-20230829","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/nrrheum.2012.37","article-title":"New advances in juvenile spondyloarthritis","volume":"8","author":"Tse","year":"2012","journal-title":"Nat Rev Rheumatol"},{"issue":"(Suppl 2)","key":"R5-20230829","first-page":"999","article-title":"SAT0270 Low incidence of both new-onset and flares of uveitis in secukinumab-treated patients with ankylosing spondylitis: clinical trial and post-marketing safety analysis","volume":"77","author":"Deodhar","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"R6-20230829","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.rdc.2012.08.017","article-title":"Therapy for spondyloarthritis: the role of extra-articular manifestations (eye, skin)","volume":"38","author":"Carron","year":"2012","journal-title":"Rheum Dis Clin North Am"},{"key":"R7-20230829","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.rdc.2012.08.010","article-title":"Comorbidities in patients with spondyloarthritis","volume":"38","author":"van der Horst-Bruinsma","year":"2012","journal-title":"Rheum Dis Clin North Am"},{"key":"R8-20230829","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1002\/art.40568","article-title":"The eyes have it: a rheumatologist's view of uveitis","volume":"70","author":"Rosenbaum","year":"2018","journal-title":"Arthritis Rheumatol (Hoboken, NJ)"},{"key":"R9-20230829","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/00002281-200207000-00001","article-title":"Anterior uveitis: current concepts of pathogenesis and interactions with the spondyloarthropathies","volume":"14","author":"Martin","year":"2002","journal-title":"Curr Opin Rheumatol"},{"key":"R10-20230829","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1136\/ard.59.1.67","article-title":"Characterisation of uveitis in patients with psoriatic arthritis","volume":"59","author":"Paiva","year":"2000","journal-title":"Ann Rheum Dis"},{"key":"R11-20230829","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1136\/bjo.76.3.137","article-title":"Uveitis and systemic disease","volume":"76","author":"Rothova","year":"1992","journal-title":"Br J Ophthalmol"},{"key":"R12-20230829","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1001\/archopht.1997.01100150063010","article-title":"Uveitis associated with inflammatory bowel disease compared with uveitis associated with spondyloarthropathy","volume":"115","author":"Lyons","year":"1997","journal-title":"Arch Ophthalmol"},{"key":"R13-20230829","doi-asserted-by":"crossref","first-page":"5836","DOI":"10.3748\/wjg.v23.i32.5836","article-title":"Ophthalmic manifestations in patients with inflammatory bowel disease: a review","volume":"23","author":"Troncoso","year":"2017","journal-title":"World J Gastroenterol"},{"key":"R14-20230829","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ajo.2017.10.018","article-title":"Uveitis and juvenile psoriatic arthritis or psoriasis","volume":"185","author":"Salek","year":"2018","journal-title":"Am J Ophthalmol"},{"key":"R15-20230829","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s10067-015-2960-8","article-title":"Uveitis in spondyloarthritis including psoriatic arthritis, ankylosing spondylitis, and inflammatory bowel disease","volume":"34","author":"Rosenbaum","year":"2015","journal-title":"Clin Rheumatol"},{"key":"R16-20230829","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0161-6420(94)31179-1","article-title":"Posterior segment ocular manifestations in patients with HLA-B27-associated uveitis","volume":"101","author":"Rodriguez","year":"1994","journal-title":"Ophthalmology"},{"key":"R17-20230829","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/S0002-9394(00)00659-0","article-title":"Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel","volume":"130","author":"Jabs","year":"2000","journal-title":"Am J Ophthalmol"},{"key":"R18-20230829","doi-asserted-by":"crossref","first-page":"277","DOI":"10.4103\/0301-4738.114099","article-title":"Medical management of uveitis: current trends","volume":"61","author":"Babu","year":"2013","journal-title":"Indian J Ophthalmol"},{"key":"R19-20230829","first-page":"67","article-title":"Update on the use of systemic biologic agents in the treatment of noninfectious uveitis","volume":"8","author":"Pasadhika","year":"2014","journal-title":"Biologics"},{"key":"R20-20230829","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2013\/369202","article-title":"How to translate basic knowledge into clinical application of biologic therapy in spondyloarthritis","volume":"2013","author":"Chou","year":"2013","journal-title":"Clin Dev Immunol"},{"key":"R21-20230829","doi-asserted-by":"crossref","first-page":"3246","DOI":"10.1167\/iovs.06-1444","article-title":"The role of soluble TNF receptors for TNF-alpha in uveitis","volume":"48","author":"Sugita","year":"2007","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R22-20230829","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.berh.2018.08.002","article-title":"Uveitis and spondyloarthropathies","volume":"31","author":"Sharma","year":"2017","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"R23-20230829","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/ncprheum0097","article-title":"Does anti-TNF therapy decrease the incidence of anterior uveitis in patients with ankylosing spondylitis?","volume":"2","author":"Levy-Clarke","year":"2006","journal-title":"Nat Clin Pract Rheumatol"},{"key":"R24-20230829","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1016\/S0161-6420(02)01292-7","article-title":"Antitumor necrosis factor-alpha therapy with infliximab as an alternative to corticosteroids in the treatment of human leukocyte antigen B27-associated acute anterior uveitis","volume":"109","author":"El-Shabrawi","year":"2002","journal-title":"Ophthalmology"},{"key":"R25-20230829","first-page":"2515","article-title":"Comparing the risk of developing uveitis in patients initiating antitumor necrosis factor therapy for ankylosing spondylitis: an analysis of a large US claims database","volume":"30","author":"Wendling","year":"2014","journal-title":"Immunology"},{"key":"R26-20230829","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1136\/ard.2008.092585","article-title":"Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study","volume":"68","author":"Rudwaleit","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"R27-20230829","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1002\/art.21197","article-title":"Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the antitumor necrosis factor agents infliximab and etanercept","volume":"52","author":"Braun","year":"2005","journal-title":"Arthritis Rheum"},{"key":"R28-20230829","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1056\/NEJMoa1509852","article-title":"Adalimumab in patients with active noninfectious uveitis","volume":"375","author":"Jaffe","year":"2016","journal-title":"N Engl J Med"},{"key":"R29-20230829","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/S0140-6736(16)31339-3","article-title":"Adalimumab for prevention of uveitic flare in patients with inactive noninfectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial","volume":"388","author":"Nguyen","year":"2016","journal-title":"Lancet (London, England)"},{"key":"R30-20230829","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/j.ophtha.2017.12.039","article-title":"Safety and efficacy of adalimumab in patients with noninfectious uveitis in an ongoing open-label study: VISUAL III","volume":"125","author":"Suhler","year":"2018","journal-title":"Ophthalmology"},{"key":"R31-20230829","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1056\/NEJMoa1614160","article-title":"Adalimumab plus methotrexate for uveitis in juvenile idiopathic arthritis","volume":"376","author":"Ramanan","year":"2017","journal-title":"N Engl J Med"},{"key":"R32-20230829","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1745-6215-15-14","article-title":"A randomised controlled trial of the clinical effectiveness, safety and cost-effectiveness of adalimumab in combination with methotrexate for the treatment of juvenile idiopathic arthritis associated uveitis (SYCAMORE Trial)","volume":"15","author":"Ramanan","year":"2014","journal-title":"Trials"},{"key":"R33-20230829","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1136\/ard.2006.052092","article-title":"Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study","volume":"65","author":"Guignard","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"R34-20230829","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.ophtha.2013.09.048","article-title":"Expert panel recommendations for the use of antitumor necrosis factor biologic agents in patients with ocular inflammatory disorders","volume":"121","author":"Levy-Clarke","year":"2014","journal-title":"Ophthalmology"},{"issue":"(Suppl 2)","key":"R35-20230829","first-page":"350","article-title":"THU0381 Certolizumab pegol is effective in uveitis associated to spondyloarthritis refractory to other tumour necrosis factor inhibitors","volume":"76","author":"Hern\u00e1ndez","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"R36-20230829","first-page":"167","article-title":"Certolizumab pegol, a new anti-TNF-alpha in the armamentarium against ocular inflammation","volume":"24","author":"Llorenc","year":"2016","journal-title":"Ocul Immunol Inflamm"},{"key":"R37-20230829","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1002\/acr.22848","article-title":"Observed incidence of uveitis following certolizumab pegol treatment in patients with axial spondyloarthritis","volume":"68","author":"Rudwaleit","year":"2016","journal-title":"Arthritis Care Res"},{"key":"R38-20230829","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.semarthrit.2016.03.002","article-title":"Golimumab in refractory uveitis related to spondyloarthritis. Multicenter study of 15 patients","volume":"46","author":"Calvo-Rio","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"R39-20230829","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1111\/ceo.12207","article-title":"Treatment of seronegative spondyloarthropathy-associated uveitis with golimumab: retrospective case series","volume":"42","author":"Faez","year":"2014","journal-title":"Clin Exp Ophthalmol"},{"key":"R40-20230829","doi-asserted-by":"crossref","first-page":"e000239","DOI":"10.1136\/rmdopen-2015-000239","article-title":"Paradoxical reactions under TNF-\u03b1 blocking agents and other biological agents given for chronic immune-mediated diseases: an analytical and comprehensive overview","volume":"2","author":"Toussirot","year":"2016","journal-title":"RMD Open"},{"key":"R41-20230829","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1093\/rheumatology\/ken091","article-title":"Do TNF-blockers reduce or induce uveitis?","volume":"47","author":"Cobo-Ibanez","year":"2008","journal-title":"Rheumatology (Oxford, England)"},{"key":"R42-20230829","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.semarthrit.2011.05.005","article-title":"New onset of uveitis during antitumor necrosis factor treatment for rheumatic diseases","volume":"41","author":"Wendling","year":"2011","journal-title":"Semin Arthritis Rheum"},{"key":"R43-20230829","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1136\/annrheumdis-2016-210931","article-title":"Tumour necrosis factor inhibitor treatment and occurrence of anterior uveitis in ankylosing spondylitis: results from the Swedish biologics register","volume":"76","author":"Lie","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"R44-20230829","doi-asserted-by":"crossref","first-page":"3248","DOI":"10.1002\/art.22918","article-title":"Do tumor necrosis factor inhibitors cause uveitis? A registry-based study","volume":"56","author":"Lim","year":"2007","journal-title":"Arthritis Rheum"},{"key":"R45-20230829","first-page":"1","article-title":"[Can tumor necrosis factor inhibitors induce sclero-uveitis?]","volume":"32","author":"Le Garrec","year":"2009","journal-title":"J Fr Ophtalmol"},{"key":"R46-20230829","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1097\/BOR.0000000000000301","article-title":"Targeting the interleukin-23\/17 axis in axial spondyloarthritis","volume":"28","author":"Paine","year":"2016","journal-title":"Curr Opin Rheumatol"},{"key":"R47-20230829","doi-asserted-by":"crossref","first-page":"628","DOI":"10.4103\/0301-4738.194339","article-title":"Roles of interleukin-17 in uveitis","volume":"64","author":"Guedes","year":"2016","journal-title":"Indian J Ophthalmol"},{"key":"R48-20230829","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1016\/j.ophtha.2018.05.014","article-title":"Targeting interleukin-23 in the treatment of noninfectious uveitis","volume":"125","author":"Pepple","year":"2018","journal-title":"Ophthalmology"},{"key":"R49-20230829","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s00417-014-2567-9","article-title":"The expression and significance of T helper cell subsets and regulatory T cells CD(4)(+) CD(2)(5)(+) in peripheral blood of patients with human leukocyte antigen B27-positive acute anterior uveitis","volume":"252","author":"Zou","year":"2014","journal-title":"Graefe's Arch Clin Exp Ophthalmol"},{"key":"R50-20230829","doi-asserted-by":"crossref","first-page":"R18","DOI":"10.1186\/ar3697","article-title":"Neutralization of IL-17 ameliorates uveitis but damages photoreceptors in a murine model of spondyloarthritis","volume":"14","author":"Kezic","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"R51-20230829","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1097\/IIO.0000000000000070","article-title":"Clinical trials in noninfectious uveitis","volume":"55","author":"Kim","year":"2015","journal-title":"Int Ophthalmol Clin"},{"key":"R52-20230829","doi-asserted-by":"crossref","first-page":"367","DOI":"10.3899\/jrheum.170429","article-title":"Efficacy and safety of ixekizumab in patients with active psoriatic arthritis: 52-week results from a Phase III study (SPIRIT-P1)","volume":"45","author":"van der Heijde","year":"2018","journal-title":"J Rheumatol"},{"key":"R54-20230829","doi-asserted-by":"crossref","DOI":"10.1111\/dth.12527","article-title":"Successful ustekinumab treatment of noninfectious uveitis and concomitant severe psoriatic arthritis and plaque psoriasis","volume":"30","author":"Mugheddu","year":"2017","journal-title":"Dermatol Ther"},{"key":"R55-20230829","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1136\/annrheumdis-2018-213328","article-title":"Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study","volume":"77","author":"Baeten","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"R56-20230829","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/art.40759","article-title":"Ustekinumab fails to show efficacy in a phase III axial spondyloarthritis program: the importance of negative results","volume":"71","author":"Mease","year":"2019","journal-title":"Arthritis Rheumatol (Hoboken, NJ)"},{"key":"R57-20230829","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1002\/art.33404","article-title":"Interferon-\u03b3 regulates discordant mechanisms of uveitis versus joint and axial disease in a murine model resembling spondylarthritis","volume":"64","author":"Kezic","year":"2012","journal-title":"Arthritis Rheum"},{"key":"R58-20230829","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/nature05505","article-title":"Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis","volume":"445","author":"Zheng","year":"2007","journal-title":"Nature"},{"key":"R59-20230829","doi-asserted-by":"crossref","first-page":"5147","DOI":"10.4049\/jimmunol.181.7.5147","article-title":"Gene expression profiling in autoimmune noninfectious uveitis disease","volume":"181","author":"Li","year":"2008","journal-title":"J Immunol"},{"key":"R60-20230829","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1136\/annrheumdis-2016-210322","article-title":"Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study","volume":"76","author":"van der Heijde","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"R62-20230829","doi-asserted-by":"crossref","first-page":"4","DOI":"10.4103\/0976-9668.175016","article-title":"Vedolizumab: a novel antiintegrin drug for treatment of inflammatory bowel disease","volume":"7","author":"Singh","year":"2016","journal-title":"J Nat Sci Biol Med"},{"key":"R63-20230829","doi-asserted-by":"crossref","DOI":"10.1093\/ibd\/izy065","article-title":"Extraintestinal manifestations in vedolizumab and anti-TNF-treated patients with inflammatory bowel disease","author":"Dubinsky","year":"2018","journal-title":"Inflamm Bowel Dis"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00002281-201907000-00006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T06:38:51Z","timestamp":1693291131000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002281-201907000-00006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":61,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000000619","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7]]}}}